Draup Sales
Request Demo
The Road Ahead for Med-Tech Firms
The Road Ahead for Med-Tech Firms
Ganesh Subramaniam

Senior Consultant at Draup

Share

The Road Ahead for Med-Tech Firms

01 Oct 2018
Our deep-dive reveals that the global ER&D spend is highly consolidated among the top 5 OEMs with imaging and non-imaging devices being the primary spend segments.

Draup’s latest study on the medical devices space has revealed interesting insights about emerging digitization and globalization strategies of medical device OEMs and the opportunities available. The medical device industry is poised for steady growth towards digitization, with aggregated annual R&D spends expected to reach $27 billion by 2021. They are also expected to increase the spend towards software skills by ~11% in the next 5 years with the Bay Area and Bengaluru emerging as key hotspots for setting up Digital CoEs.

Medical devices R&D is highly consolidated in the US. Most hubs are in North America, clearly indicating who’s in charge of the decision-making. Tech giants are building software-centric solutions out of the Bay area and have developed a rich medical device ecosystem. Medical device giants have accelerated capabilities focused on product and systems development in Boston towards the East Coast.

Medical devices R&D footprint